Eurasian Journal of Applied Biotechnology, 2018, № 1
ROLE OF MONOCLONAL ANTIBODIES AGAINST THE PROGRAMMABLE DEATH (PD-1) RECEPTOR OF T-CELLS IN TARGETED THERAPY OF MELANOMA
Аннотация · Abstract
Oncogenic cells have intrinsic properties for evading attack by the immune system, which largely contribute to the oncogenic pathology. Therefore, the development of drugs that can block these properties represents an important goal toward obtaining effective strategies to cure cancer. Currently, monoclonal antibodies targeting the programmable cell death 1 (PD-1) receptor and its ligand (PD-L1) are widely used in targeted therapy, which show high effectivity in clinical studies resulting in a significant increase in the duration of anticancer immunity. The PD-1/PD-L1 signaling pathway was recently identified as a mechanism of the negative regulation of the immune system, and as the main mechanism by which oncogenic cells evade the body’s immune system. Moreover, the expression of PD-1 receptor in the tumour microenvironment cells is related to several other signaling pathways involving both hematopoietic and non-hematopoietic cells. The interaction of PD-1 and PD-L1 inhibits the activity of cytotoxic T-cells and tumour-infiltrating lymphocytes with increased T-cell suppressor activity. Consequently, the PD-1/PD-L1 signaling pathway promotes tumour cells to evade the immune response. Therefore, blockage of PD-1/PD-L1 enhances antitumor immunity, reduces the number of T-cell suppressors and suppresses their activity, and restores the activity of cytotoxic T-cells. The PD1 receptor and it is ligands PD-L1 and PD-L2 are representatives of the immunoglobulin superfamily and are part of the "immunological control points" system, the main functions of which include the regulation and modulation of the immune response, reduction of immune cell-induced damage in organs and tissues, and prevention of autoimmune processes. Accordingly, development of therapeutic anti-PD1 and anti-PD-L1 monoclonal antibodies that could lead to the reactivation of a specific antitumor immune response is a promising strategy of tumour immunotherapy. To date, monoclonal antibodies blocking PD-1/PD-L1 have achieved good results and were approved by the Food and Drug Administration.
Сведения · Details
- DOI 10.11134/btp.1.2018.3
- Журнал · Journal Eurasian Journal of Applied Biotechnology
- Язык · Language английский
- Цитирования (Crossref) · Citations 0